Certolizumab pegol attenuates the pro-inflammatory state in endothelial cells in a manner that is atheroprotective.
about
The effect of type 1 IFN on human aortic endothelial cell function in vitro: relevance to systemic lupus erythematosus.What is the future of targeted therapy in rheumatology: biologics or small molecules?Endothelial microparticles prevent lipid-induced endothelial damage via Akt/eNOS signaling and reduced oxidative stress.Extracellular Vesicles: How Drug and Pathology Interfere With Their Biogenesis and Function
P2860
Certolizumab pegol attenuates the pro-inflammatory state in endothelial cells in a manner that is atheroprotective.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Certolizumab pegol attenuates ...... nner that is atheroprotective.
@en
Certolizumab pegol attenuates ...... nner that is atheroprotective.
@nl
type
label
Certolizumab pegol attenuates ...... nner that is atheroprotective.
@en
Certolizumab pegol attenuates ...... nner that is atheroprotective.
@nl
prefLabel
Certolizumab pegol attenuates ...... nner that is atheroprotective.
@en
Certolizumab pegol attenuates ...... nner that is atheroprotective.
@nl
P2093
P1476
Certolizumab pegol attenuates ...... anner that is atheroprotective
@en
P2093
Ian N Bruce
Leo A H Zeef
M Yvonne Alexander
Sarah K Heathfield
P304
P50
P577
2012-12-13T00:00:00Z